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http://www.biomedcentral.com/1472-6882/14/481RESEARCH ARTICLE Open AccessAngelica sinensis extract inhibits RANKL-mediated
osteoclastogenesis by down-regulated the
expression of NFATc1 in mouse bone marrow cells
Lingbo Kong1†, Qinpeng Zhao1†, Xiaodong Wang1, Jinyu Zhu2, Dingjun Hao1* and Chongfei Yang2*Abstract
Background: Destructive erosion of bone or osteolysis is a major complication of inflammatory conditions such as
rheumatoid arthritis (RA), periodontal disease, and periprosthetic osteolysis. Natural plant-derived products have
received recent attention as potential therapeutic and preventative drugs in human disease.
Methods: The effect of Angelica sinensis (AS) extract on RANKL-induced osteoclast differentiation was examined in
this study. The osteoclast precursor cell line bone marrow macrophages (BMMs) was cultured and stimulated with
RANKL followed by treatment with AS at several doses. Gene expression profiles of c-Fos, c-Jun, NFATc1, TRAP, and
OSCAR were sequentially evaluated.
Results: AS extract inhibited RANKL-mediated osteoclast differentiation in BMMs in a dose-dependent manner
without any evidence of cytotoxicity. AS extract strongly inhibited p38, ERK, JNK, p65 phosphorylation and I-κB
degradation in RANKL-stimulated BMMs. AS extract also inhibited the mRNA expression of c-Fos, c-Jun, NFATc1,
TRAP, and OSCAR in RANKL-treated BMMs. Moreover, RANKL-induced c-Fos, c-Jun and NFATc1 protein expression
was suppressed by AS extract.
Conclusions: These results collectively suggested that AS extract demonstrated inhibitory effects on RANKL-mediated
osteoclast differentiation in bone marrow macrophages in vitro, indicating that AS may therefore serve as a useful drug
in the prevention of bone loss.
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Osteoclasts are derived from hematopoietic stem cells,
which are unique multinucleated cells responsible for
bone resorption [1]. Osteoblasts and stromal cells express
receptor activators of the nuclear factor-kB (NF-kB) ligand
(RANKL) and macrophage colony-stimulating factor (M-
CSF) [2]. M-CSF induces expression of RANKL receptor
(RANK) as well as supports survival and proliferation in
early stage precursors of osteoclast lineages in mouse bone
marrow cells [3]. RANKL is a member of the tumor ne-
crosis factor (TNF) family and binds to the RANK recep-
tor expressed in osteoclast precursor cells [4]. The binding* Correspondence: dhao.honghui@outlook.com; jinyuzhu@outlook.com
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unless otherwise stated.of RANKL and RANK on osteoclast progenitor cells trig-
gers the activation of tumor necrosis factor receptor-
associated factor 6 (TRAF6) [5] and subsequently the acti-
vation of NF-kB and mitogen-activated protein kinases
(MAPKs), such as extracellular signal-regulated kinase 1/2
(ERK1/2), p38 and stressactivated protein kinase/c-Jun N-
terminal kinase (SAPK/JNK) [6,7]. Although more detailed
mechanism is still expected to be unveiled, the major
signaling events triggered upon RANK ligation include re-
cruitment of TRAF6, the activation of transcription factors
NF-κB, c-Fos, AP-1, and nuclear factor of activated T cells
(NFATc1) [2,5,8-11]. NFATc1 is a downstream tran-
scription factor in the RANKL/RANK signal pathway
and as a key molecule of osteoclastogenesis, NFATc1
induces a series of osteoclast-specific genes, including
tartrate-resistant acid phosphatase (TRAP), osteoclast-
associated receptor (OSCAR) and cathepsin K −[12,13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clastogenesis and positively regulates osteoclastogene-
sis via NFATc1 activation [14].
Many plant-derived natural products have been used
in traditional medicine for the treatment of various dis-
eases. Several compounds derived from natural products
have been recently reported to possess inhibitory effects
on osteoclast differentiation and function, leading to de-
creased bone loss in vivo [1]. Angelica sinensis (AS) has
been used to regulate menstruation, an inflammatory
syndrome, in Asia for thousands of years. Recently, a
component of AS extract, ligustilide has been reported
to regulate several extracellular signaling pathways, in-
cluding ERK1/2, p38 and SAPK/JNK [15]. Additionally,
our previous study demonstrated that AS extract could
inhibit wear debris particles-induced bone resorption by
attenuating proinflammatory cytokines [16]. However,
the effects of AS extract on RANKL and M-CSF func-
tions vital to osteoclast differentiation are not clarified.
In this study, we aimed to investigate the effects of AS
extract on signaling pathways involved in osteoclast dif-
ferentiation, activation, and survival in vitro.
Methods
Herb preparation
Dry root slices of a popular Chinese herb, Angelica
sinensis (Dang Gui), was obtained from Tong Ren Tang
(Tong Ren Tang Group Co., Ltd.; Beijing, China) and ex-
tracted in water (85°C) for 4 h. The water-soluble frac-
tion was cleared sequentially by centrifugation (3300 × g,
20 min, 4°C) and filtration through a 0.2 mm filter [17].
From10 g dry Angelica sinensis root, about 0.8 g yellow,
powdery substance was recovered after lyophilization.
Reagents and antibodies
Human RANKL and M-CSF was obtained from Pepro-
tech (London, UK). The XTT assay kit was obtained
from Roche (Indianapolis, IN, USA). Antibodies for c-
Fos, c-Jun and nuclear factor of activated T cells 1
(NFATc1) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA), and Western blot antibodies
for phosphor-p65, p-65, phosphor-ERK, ERK, phosphor-
JNK, JNK, phosphor-p38, p38, and I-κB were from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA); β-actin
antibody was purchased from Sigma-Aldrich, Inc. (St.
Louis, MO, USA).
Osteoclast differentiation
All the animal work and approach have been approved
by the IACUC of the Hong-Hui Hospital, Xi’an Jiaotong
University College of Medicine and conducted strictly
followed by “the institutional guidelines for the care and
use of laboratory animals at the Jiaotong University Col-
lege of Medicine”. Bone marrow cells were obtained byflushing the femurs and tibiae of 5-week-old ICR mice
with α-minimum essential medium (α-MEM; Gibco
BRL, Gaithersburg, MD, USA) and suspended in α-
MEM supplemented with 10% fetal bovine serum (FBS;
Gibco BRL, Gaithersburg, MD, USA). Non-adherent
cells were collected and cultured for 3 days in the pres-
ence of M-CSF (20 ng/ml). Floating cells were discarded
and adherent cells on dish bottoms were classified as
bone marrow derived macrophages (BMMs). BMMs
were seeded at 3.5 × 104 cells/well in α-MEM/10% FBS,
and were cultured in the presence of M-CSF (20 ng/ml)
and RANKL (40 ng/ml) for 4 days in the presence or ab-
sence of AS extract. Osteoclasts were identified by staining
for tartrate-resistant acid phosphatase (TRAP) activity, as
described below. TRAP-positive multinucleated cells with
greater than three nuclei were counted as osteoclasts.
Cytotoxicity assay for AS extract treated BMMs were
plated in 96-well plates at a density of 1 × 104 cells/well in
triplicate. Cells were treated with M-CSF (20 ng/ml) and
increasing concentrations of AS extract were added to the
mix. Cells were incubated for 3 days. After 3 days, XTT
reagent (50 μl) was added to each well. Wells were incu-
bated for 4 h. The optical density at 450 nm was analyzed
with an ELISA reader.
Clonogenic assay
RAW 264.7 cells were seeded in 48-well plates at a dens-
ity of 3 × 103cells/well in triplicate and cultured for
4 days in the presence of increasing concentrations of
AS extract. After 4 days, the cells were fixed and stained
with Hematoxylin Sigma-Aldrich, Inc. (St. Louis, MO,
USA). Colonies with 50 or greater cells were counted.
Real time RT-PCR analysis for c-Fos, c-Jun, NFATc1, TRAP,
osteoclast-associated receptor (OSCAR)
Total RNA was isolated with TRIzol reagent (Invitrogen
Inc., USA) per the manufacturer’s instructions. RNA
(1 μg) was reverse transcribed using oligo dT primers
(10 μg) and dNTPs (10 mM). The mixture was incubated
at 65°C for 5 min, and cDNA was produced by incubating
at 42°C for 50 min with first strand buffer (50 mM Tris–
HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2), 100 mM DTT,
RNase inhibitor, and Superscript II reverse transcriptase
(Invitrogen). The cDNA was amplified using the following
primer sets: c-Fos, 5′-CTGGTGCAGCCCACTCTGGTC-
3′ (forward) and 5′-CTTTCAGCAGATTGGCAATCTC-
3′ (reverse); c-Jun, 5′-ACT CGG ACC TTC TCA CGT
CG- 3′ (forward) and 5′-TAG ACC GGA GGC TCA
CTG TG −3′ (reverse); NFATc1, 5′-CTCGAAAGACAG
CACTGGAGCAT-3′ (forward) and 5′-CGGCTGCCTTC
CGTCTCATAG-3′ (reverse); TRAP, 5′-CTGGAGTGCA
CGATGCCAGCGACA-3′ (forward) and 5′-TCCGTGC
TCGGCGATGGACCAGA-3′ (reverse); OSCAR, 5′-CTG
CTGGTAACGGATCAGCTCCCCAGA-3′ (forward) and
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and GAPDH, 5′-ACCACAGTCCATGCCATCAC-3′ (for-
ward) and 5′-TCCACCACCCTGTTGCTGTA- 3′(re-
verse). PCR was performed using the QuantiTect SYBR
Green PCR kit (Qiagen) in triplicates according to the
manufacturer’s instructions. Relative levels of c-Fos, c-Jun,
NFATc1, TRAP, and OSCAR were normalized to GAPDH.
Western blot analysis
BMMs or osteoclasts were lysed in a buffer containing
50 mM Tris–HCl, 150 mM NaCl, 5 mM EDTA, 1% Tri-
ton X-100, 1 mM sodium fluoride, 1 mM sodium vanad-
ate, 1% deoxycholate, and protease inhibitors. The
lysates were centrifuged at 14,000 × g for 20 min and
supernatants were collected. Protein concentrations
of supernatants were determined. Cellular proteins
(30 μg) were resolved by 8–10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) andFigure 1 Effect of AS extract on RANKL-induced osteoclast differentia
RANKL (40 ng/ml) in the presence of varying concentrations of AS extract.
X-100, and stained with TRAP solution. (B) TRAP-positive cells were counte
(p < 0.05) between control and treated. (C) Cytotoxicity of AS extract on BM
extract in the presence of M-CSF (20 ng/ml). XTT solution (50 μl) was adde
optical density was measured at 450 nm. (D) RAW 264.7 cells were seeded
concentrations of AS extract for 4 days. After 4 days, the cells were fixed an
counted. Similar results were obtained in at least 3 independent experimenwere transferred to polyvinylidene difluoride membranes
(Milipore, Bedford, MA, USA). Non-specific inte-
ractions were blocked with 5% skim milk for 2 h and
were then probed with the appropriate primary anti-
bodies. Membranes were incubated with the appro-
priate secondary antibodies attached to horseradish
peroxidase, and immunoreactivity was detected with
enhanced chemiluminescence reagents. Densitometric
values were quantified for each band with the Image
Pro-plus program version 4.0.
Statistical analysis
All data are expressed as means ± standard deviation
(SD). Statistical analysis was done using SPSS software
package ver. 11.0 (SPSS, Chicago, IL); one-way ANOVA
was used for comparison among the different groups.
Post hoc testing of differences between groups was per-
formed by using Duncan’s test when the ANOVA wastion. (A) BMMs were cultured for 4 days with M-CSF (20 ng/ml) and
Cells were fixed with 3.7% formalin, permeabilized with 0.1% Triton
d as osteoclasts. Asterisk indicates a statistically significant difference
Ms. BMMs were cultured for 3 days with varying concentrations of AS
d to each well after 3 days, and plates were incubated for 4 h. The
at 3000 cells/plate in 48-well plates and cultured with the indicated
d stained with Hematoxylin. Colonies with 50 or greater cells were
ts.
Figure 2 Effect of AS extract on RANKL-induced MAPKs and
NF-κB activation. AS extract inhibits the p38, ERK, JNK, p65
phosphorylation and I-κB degradation in RANKL-stimulated BMMs. BMMs
were pretreated with or without AS extract (50 mg/l) for 1 h prior to
RANKL stimulation (100 ng/ml) at indicated time periods. Cells were
lysed in lysis buffer, and lysates were analyzed by Western blotting with
indicated antibodies. The intensities of protein bands were analyzed
and normalized to actin. Similar results were obtained in at least 3
ndependent iexperiments.
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at the 5% critical level (P < 0.05).
Results
Inhibition of osteoclast differentiation by AS extract
Osteoclasts were generated from mouse BMMs in the
presence of M-CSF (20 ng/ml) plus RANKL (40 ng/ml)
to verify the effects of AS extract in osteoclastogenesis.
The BMMs of the control group differentiated into ma-
ture TRAP-positive multinucleated osteoclasts while AS
extract reduced the formation and numbers of TRAP-
positive multinucleated cells in a dose-dependent man-
ner (Figure 1A, B).
The cytotoxic effect of AS extract
AS extract generated a highly negative effect on osteo-
clastogenesis. We measured the effects of AS extract on
bone marrow cells with the XTT assay to exclude the
possibility that the inhibition was due to cytotoxicity. AS
extract demonstrated no cytotoxic effects at the same
doses which effectively inhibited osteoclast formation
(Figure 1C). Also, AS extract did not affect in RAW
264.7 cells colony formation (Figure 1D), suggesting that
osteoclastogenesis suppression by AS extract was not
due to toxic effects on BMMs.
AS extract inhibits a variety of signals transduced by
RANKL
RANKL activates a variety of signal transducers that are
involved in osteoclastogenesis, including p38, JNK, ERK,
transcription factor NF-κB and I-κB, which are recognized
as the key factors of osteoclast differentiation [2,3]. Osteo-
clast precursors were pretreated with AS extract and stim-
ulated with RANKL at various time points. Different
signaling pathways were observed. Activation of ERK,
JNK, p38, NF-κB p65 and degradation of I-κB by RANKL
were all significantly inhibited by AS extract (Figure 2).
RANKL induced c-Fos, c-Jun, NFATc1, TRAP, and OSCAR
mRNA expression is reduced by AS extract
Osteoclast differentiation is regulated by the induction
of various genes in response to RANKL and RANK
binding. The c-Fos, c-Jun and NFATc1 genes have an es-
sential role in the osteoclast differentiation [2,13], and
NFATc1 regulates OSCAR expression [18]. We exam-
ined the effects of AS extract on the RANKL-induced
regulation of c-Fos, c-Jun and NFATc1 expression, and
to assess whether there were any effects on TRAP and
OSCAR expression. Osteoclast precursors were pre-
treated with AS extract and further stimulated with
RANKL at various time points. Results revealed that c-
Fos, c-Jun and NFATc1 mRNA levels were increased in re-
sponse to RANKL, but c-Fos, c-Jun and NFATc1 mRNA
expression was significantly inhibited by AS extract.Moreover TRAP and OSCAR mRNA expression was also
significantly inhibited by AS extract (Figure 3A). This
raises the possibility that, AS extract may inhibit osteoclast
differentiation through the inhibition of RANKL-induced
c-Fos, c-Jun and NFATc1 expression.
Figure 3 (See legend on next page.)
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Figure 3 AS extract suppresses the mRNA expression of c-Fos, c-Jun, NFATc1, OSCAR and TRAP in BMMs treated with RANKL. (A)
BMMs were pretreated with or without AS extract (50 mg/l) for 1 h and with RANKL (100 ng/ml) for the indicated time. Total RNA was isolated
using TRIzol, and 1 μg of total RNA was used to transcribe cDNA. cDNA (1 μl) was used as a template for real time RT-PCR. The mRNA expression
of the indicated genes was analyzed by real time RT-PCR. (B) AS extract inhibits the expression of c-Jun, c-Fos and NFATc1 induced by RANKL.
BMMs were pretreated with or without AS extract (50 mg/l) for 1 h and were treated with RANKL (100 ng/ml) for the indicated time. Cells were
lysed in the lysis buffer, and lysates were analyzed by Western blotting with antibodies against c-Jun, c-Fos, NFATc1 and actin. The intensities of
the protein bands were analyzed and normalized to actin. Similar results were obtained in at least 3 independent experiments.
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Western blots were examined to verify the effects of AS
extract on c-Fos, c-Jun and NFATc1 protein expression.
c-Fos, c-Jun and NFATc1 protein levels were increased
in response to RANKL, but c-Fos, c-Jun and NFATc1
expression was significantly inhibited by AS extract
(Figure 3B). These results demonstrated that the inhibitory
effects of AS extract involved the inhibition of major
transcription factors such as c-Fos, c-Jun and NFATc1.
Discussion
Bone resorption by osteoclasts is frequently caused by
excessive RANKL signaling which has been a valuable
target for the treatment of pathological bone loss.
RANKL activates a series of major intracellular signal
transducing pathways including NFATc1, NF-κB, phos-
phoinositide 3 kinase (PI3K)-Akt, JNK, ERK, and p38
MAPK. AS is one of the most popular Chinese herbs in
both clinical field and research field. Su et al. [15] re-
ported that a component of AS extract: ligustilide sup-
presses the LPS-induced production of NO, PGE2 and
TNF-α by inhibiting both IKK/NF-κB and MAPK/AP-1
signaling. Recently we [16] demonstrated that AS extract
could inhibit bone resorption by attenuating proinflamma-
tory cytokines. However, the effect of AS extract on
RANKL-induced osteoclast formation, especially RANKL-
mediated intracellular signal pathway still is an interesting
question that remains to be investigated.
The MAPK group of enzymes selectively phosphory-
lates serine and threonine residues in response to extra-
cellular stimuli and transmits the stimuli from the cell
surface to the nucleus [7]. MAPK is primarily composed
of JNK, ERK, and p38 in mammalian cells. RANKL and
RANK receptor binding expressed in osteoclast pre-
cursors provides a link between distinct signaling mole-
cules such as JNK, ERK, and p38 MAPK [1]. p38 MAPK
signaling is particularly crucial in the early stages of
osteoclast differentiation as it promotes the activity of
microphthalmia-associated transcription factor (MITF)
and TRAP expression. Inhibition of p38 MAPK with
SB203580 has a negative effect on osteoclast formation
[19]. AS extract suppressed RANKL-induced the phos-
phorylation of p38, ERK and JNK activity in the present
study (Figure 2).The activation of signaling molecules induces tran-
scription factors such as NF-κB, NFATc1, and AP-1 that
are essential for osteoclast differentiation [20]. NF-κB is
an important signal mediator for inflammatory and im-
mune reactions and is a major transcription factor for
RANKL-activated osteoclastogenesis [21]. I-κB is at-
tached to NF-κB preventing it from migrating into the
nucleus, and phosphorylation with I-κB kinase (IKK)
separates the two proteins. Subsequent ubiquitination
and proteosome degradation of I-κB allows the transfer
of NF-κB into the nucleus and transcription of the target
gene [22]. Although our previous study showed that one
factor of AS extract: ligustilide decreases NF-κB lucifer-
ase activity in a reporter assay [16], we also confirmed
that AS extract inhibits NF-κB/I-κB protein expression
in this experiments. These results are consistent with
RANKL activation of NF-κB in osteoclastic precursor
cells through IKK activation and susequent I-κB phos-
phorylation and degradation (Figure 2).
NFATc1 is a master regulator of osteoclastogenesis
which autoamplifies and conducts the expression of osteo-
clast specific genes such as activator protein-1 (AP-1),
TRAP, calcitonin receptor, OSCAR, and cathepsin K
[10,23-25]. The RANKL-induced NFATc1 expression is
mediated by the activation of AP-1 consisting of c-Fos and
c-Jun [26,27]. c-Fos was reported to be critical for tran-
scriptional activation of NFATc1 in RANKL-induced osteo-
clastogenesis [7]. Putative c-Fos binding sites were mapped
in the promoter region of NFATc1, and the NFATc1 ex-
pression was abolished in the osteoclast precursors lacking
c-Fos [11].On the other hand, Ikeda et al. [26] reported that
RANKL could not induce expression of NFATc1 in
dominant-negative c-Jun transgenic mouse. It is possible
that the induction of NFATc1 may be cooperatively up-
regulated by c-Fos and c-Jun, which make up each other
for the induction [28]. The present study demonstrates the
reduced both c-Fos and c-Jun expression in AS extract
treated BMM cells (Figure 3). Therefore, the reduced c-Fos
and c-Jun expression is suggested to cause the impaired ac-
tivation of NFATc1, followed by the inhibition of RANKL-
induced osteoclast formation. Additionally mRNA levels of
major osteoclast marker TRAP and OSCAR was also
inhibited by AS extract (Figure 3). These data suggest that
the AP-1 transcription factor is the targets of AS extract-
induced inhibition of osteoclastogenesis.
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In summary, the present study demonstrated that AS
inhibited osteoclastogenesis from macrophages and bone
resorption in vitro. AS also reduced the RANKL-induced
expression of osteoclastic marker genes. In addition, AS
attenuated RANKL-induced ERK, p38, JNK, NF-κB, AP-1
and NFATc1 activation. Although additional experiments
are needed to confirm the efficacy of AS in treating disease
conditions in vivo, our results indicate that AS has poten-
tial as a therapy for disorders associated with bone loss.
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